Gland Pharma receives USFDA approval for Cetrorelix Acetate injection

29 Apr 2024 , 01:37 PM

Gland Pharma has received United States Food and Drug Administration (USFDA) approval for Cetrorelix Acetate for injection.

The company anticipates launching this product soon in collaboration with its marketing partner. Cetrorelix Acetate is primarily used to prevent premature LH (luteinizing hormone) surges in women undergoing controlled ovarian stimulation.

It works by blocking the effects of a hormone called gonadotropin-releasing hormone (GnRH), which regulates the secretion of LH, responsible for inducing ovulation during the menstrual cycle.

Gland Pharma views the approval of Cetrorelix as an expansion of its fertility product line, reflecting its dedication to developing and manufacturing intricate injectables to address patients’ unmet medical needs.

Currently, Gland Pharma’s shares are trading at ₹1,713 on the BSE, marking a decline of ₹15.35 or 0.89%. Over the past year, the stock has gained 24.52%, but it has experienced a decrease of 10.15% since the beginning of the year. The stock reached its 52-week high of ₹2,195.75 on February 7, 2024, and its 52-week low of ₹861.50 on May 22, 2023.

For feedback and suggestions, write to us at [e-mail]